BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33015785)

  • 1. LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
    Wang Y; Tan TZ; Wang LQ; Zhang K
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9429-9437. PubMed ID: 33015785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
    Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
    Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
    Yang J; Du YM; Li B
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of LncRNA FOXC2-AC1 promoting lung cancer metastasis by regulating miR-107.
    Wu XF; Lu JT; Chen W; Wang N; Meng JC; Zhou YH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):690-698. PubMed ID: 30720176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6 stimulates lncRNA ZEB2-AS1 to aggravate the progression of non-small cell lung cancer through activating STAT1.
    Chen T; Li J; Zhou MH; Xu LJ; Pan TC
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3734-3740. PubMed ID: 32329850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA FENDRR inhibits NSCLC cell growth and aggressiveness by sponging miR-761.
    Zhang MY; Zhang ZL; Cui HX; Wang RK; Fu L
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8324-8332. PubMed ID: 30556873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer.
    Song J; Su ZZ; Shen QM
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1853-1862. PubMed ID: 32141554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
    Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression.
    Yu DJ; Li YH; Zhong M
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4288-4297. PubMed ID: 32373965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.
    Yang YR; Zang SZ; Zhong CL; Li YX; Zhao SS; Feng XJ
    Int J Clin Exp Pathol; 2014; 7(10):6929-35. PubMed ID: 25400777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
    Qiu HB; Yang K; Yu HY; Liu M
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA MIR155HG knockdown suppresses cell proliferation, migration and invasion in NSCLC by upregulating TP53INP1 directly targeted by miR-155-3p and miR-155-5p.
    Ren XY; Han YD; Lin Q
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4822-4835. PubMed ID: 32432745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non-small cell lung cancer.
    Yu DJ; Li YH; Zhong M
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4800-4806. PubMed ID: 31210311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
    Liao XH; Wang Y; Zhong B; Zhu SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel long non-coding RNA LBX2-AS1 indicates poor prognosis and promotes cell proliferation and metastasis through Notch signaling in non-small cell lung cancer.
    Tang LX; Su SF; Wan Q; He P; Xhang Y; Cheng XM
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7419-7429. PubMed ID: 31539129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion.
    Dong YZ; Meng XM; Li GS
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2671-2679. PubMed ID: 29771418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.